Metrikler
Yayın
23
Açık Erişim
5
BM Sürdürülebilir Kalkınma Amaçları
Eğitim Bilgileri
2019 - Devam Ediyor
2019 - Devam EdiyorTıpta Yandal Uzmanlık
İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Türkiye
Yaptığı Tezler
2019
2019Tıpta Uzmanlık
Beta talasemi minörde serum endokan düzeyi / Serum endocan levels in beta thalassemia minor
İstanbul Üniversitesi
Yabancı Diller
B1 Orta
B1 Ortaİngilizce
Makaleler
Tümü (22)
SCI-E, SSCI, AHCI (12)
SCI-E, SSCI, AHCI, ESCI (18)
ESCI (6)
Scopus (18)
TRDizin (6)
2025
20251. Clinical factors predicting objective response to bevacizumab-based chemotherapies in advanced and recurrent epithelial ovarian cancer
Khanmammadov N., Dogan I., Okay N. S., KHISHIGSUREN B., AZİZY A., Saip P., et al.
Minerva obstetrics and gynecology
, cilt.77, sa.2, ss.112-118, 2025 (ESCI)
2025
20252. Rechallenge of trastuzumab-based therapy in HER2-positive breast cancer patients who progressed after lapatinib plus capecitabine
Khanmammadov N., Doǧan I., KHISHIGSUREN B., AZİZY A., Saip P., AYDINER A.
Medicine (United States)
, cilt.104, sa.6, 2025 (SCI-Expanded)
2025
20253. The efficacy of second-line chemotherapy in the management of classic and iatrogenic Kaposi sarcoma: An analysis of real-world data
Khanmammadov N., Ferhatoglu F., PAKSOY N., Dogan İ., KHISHIGSUREN B., Nizam N., et al.
Medicine (United States)
, cilt.104, sa.6, 2025 (SCI-Expanded)
2024
20244. Efficacy of Bevacizumab-Based Terapy in Patient With Metastatic or Recurrent Cervical Cancer: Real Life Data
KHANMAMMADOV N., Dogan I., okay n. s., Ugar M., Osmanova N., Saip P., et al.
Selçuk Tıp Dergisi
, cilt.40, sa.2, ss.68-73, 2024 (Hakemli Dergi)
2024
20245. Therapeutic efficacy of high-dose chemotherapy with autologous stem-cell transplantation in 44 relapsed or refractory germ-cell tumor patients: A retrospective cohort study
Ferhatoglu F., Paksoy N., Khanmammadov N., YILDIZ A., AHMED M. A., Gülbas Z., et al.
Medicine
, cilt.103, sa.8, 2024 (SCI-Expanded)
2024
20246. Comparative analysis of doublet chemotherapy regimens plus bevacizumab in patients with recurrent ovarian cancer
Khanmammadov N., Doǧan I., Okay N. S., AZİZY A., Saip P., AYDINER A.
Medicine (United States)
, cilt.103, sa.1, 2024 (SCI-Expanded)
2024
20247. Evaluation of the Efficacy of Bevacizumab-based Therapies in Patients with Platinum-Resistant or-Allergic Metastatic Ovarian Cancer
Khanmammadov N., Doğan İ., Okay N. S., YILDIZ A., Khishigsuren B., AZİZY A., et al.
Turk Onkoloji Dergisi
, cilt.39, sa.2, ss.176-182, 2024 (ESCI)
2024
20248. The Effect of Adjuvant Therapies for Recurrence in Stage I Breast Cancer Patients: A Single Centre Experience
Doğan İ., Khanmammadov N., Aydin E., PAKSOY N., Ferhatoğlu F., AK N., et al.
Turk Onkoloji Dergisi
, cilt.39, sa.3, ss.257-264, 2024 (ESCI, Scopus, TRDizin)
2024
20249. Outcomes of the patients with metastatic male breast cancer
Dogan I., Khanmammadov N., ÖZKURT S., AYDINER A., Saip P.
Journal of Cancer Research and Therapeutics
, cilt.20, sa.1, ss.98-102, 2024 (SCI-Expanded)
2024
202410. Efficacy of Intrathecal Therapy In Breast Cancer Patients With Leptomeningeal Metastasis
Khanmammadov N., Dogan I., AHMED M. A., YILDIZ A., Nizam N., KHISHIGSUREN B., et al.
Eastern Journal of Medicine
, cilt.29, sa.4, ss.503-508, 2024 (Scopus)
2023
202311. Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
DOĞAN İ., Aydin E., KHANMAMMADOV N., Paksoy N., Saip P., AYDINER A.
Scientific Reports
, cilt.13, sa.1, 2023 (SCI-Expanded)
2023
202312. Long-term outcomes and predictors of recurrence in node-negative early stage breast cancer patients
DOĞAN İ., Aydin E., KHANMAMMADOV N., Paksoy N., Ferhatoğlu F., AK N., et al.
Journal of Cancer Research and Clinical Oncology
, cilt.149, sa.16, ss.14833-14841, 2023 (SCI-Expanded, Scopus)
2023
202313. Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors
DOĞAN İ., KHANMAMMADOV N., PAKSOY N., VATANSEVER S., SAİP P., AYDINER A.
Eurasian Journal of Pulmonology
, cilt.25, sa.1, ss.27-32, 2023 (Hakemli Dergi)
2023
202314. Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: A real-life study
Paksoy N., KHANMAMMADOV N., DOĞAN İ., Ferhatoǧlu F., AHMED M. A., Karaman S., et al.
Medicine (Spain)
, cilt.102, sa.5, 2023 (Scopus)
2023
202315. Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience
TAŞTEKİN D., Paksoy N., DOĞAN İ., Ferhatoglu F., KHANMAMMADOV N., Bozbey H. U., et al.
Journal of cancer research and therapeutics
, cilt.19, sa.2, ss.253-258, 2023 (SCI-Expanded)
2022
202216. Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group
GÜRBÜZ M., Kilickap S., BİLİCİ A., Karadurmus N., Sezer A., ŞENDUR M. A. N., et al.
MEDICINE
, cilt.101, sa.50, 2022 (SCI-Expanded)
2022
202217. High-dose chemotherapy followed by autologous stem cell transplantation for adult patients with first relapse of Ewing's sarcoma: A single institution experience
PAKSOY N., FERHATOĞLU F., DOĞAN İ., KHANMAMMADOV N., Iribas Celik A., Gulbas Z., et al.
Medicine (United States)
, cilt.101, sa.49, 2022 (SCI-Expanded)
2022
202218. Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study
PAKSOY N., KHANMAMMADOV N., DOĞAN İ., FERHATOĞLU F., YILDIZ A., AK N., et al.
Medicine (United States)
, cilt.101, sa.45, 2022 (SCI-Expanded)
2022
202219. Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib
DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., et al.
CLINICAL CANCER INVESTIGATION JOURNAL
, sa.4, ss.5-9, 2022 (ESCI)
2022
202220. Crizotinib in Metastatic ALK mutant Non-small Cell Lung Cancer Patients: A Single Centre Experience
DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., et al.
CLINICAL CANCER INVESTIGATION JOURNAL
, sa.3, ss.25-29, 2022 (ESCI)
2022
202221. Assessment of serum endocan levels in patients with beta-thalassemia minor
Khanmammadov N., ZORLU M., ÖZER Ö. F., KARATOPRAK C., KISKAÇ M., ÇAKIRCA M.
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
, cilt.68, sa.2, ss.147-151, 2022 (SCI-Expanded)
2022
202222. Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study
Paksoy N., Ferhatoglu F., DOĞAN İ., Khanmammadov N., Bozbey H. U., KARABULUT S., et al.
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
, cilt.37, sa.4, ss.478-483, 2022 (ESCI)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2023
20231. Comparison of bevacizumab plus doublet chemotherapy regimens in patients with metastatic or recurrent ovarian cancer.
Khanmammadov N., DOĞAN İ., Saip P., Aydiner A.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 2 - 06 Haziran 2023, (Özet Bildiri)